Litigation

Recent Posts

11th Circuit Affirms Exclusion Of Plaintiff Expert In First Seroquel Bellwether
Posted on 7 Apr 2010 by Tom Moylan

ATLANTA — (Mealey’s) The sole causation expert for the first bellwether plaintiff in the Seroquel multidistrict litigation failed to rule out other causes of weight gain and diabetes, a panel of the 11th Circuit U.S. Court of Appeals said... Read More

Tags: Linda Guinn v. AstraZeneca Pharmaceuticals LP , Daubert v. Merrill Dow Pharmaceuticals , emerging drugs & devices , expert admissibility , 11th Circuit U.S. Court of Appeals , Litigation , Liknda Guinn , AstraZeneca Pharmaceuticals , Daubert , torts , Seroquel

Most FDA Advisers Recommend Avandia Stay On The Market
Posted on 14 Jul 2010 by Tom Moylan

GAITHERSBURG, Md. - (Mealey's) A majority of Food and Drug Administration advisers voted July 14 to keep Avandia on the market but split on whether the anti-diabetes drug made by GlaxoSmithKline PLC (GSK) should carry additional warnings about its... Read More

Tags: Mealey’s , Food and Drug Administration , tort , personal injury , FDA , emerging drugs & devices , diabetes drugs , Litigation , GSK , GlaxoSmithKline , Avandia